Serious Events. Should there occur serious or unexpected events or circumstances which, from a reasonable pharmaceutical company's point of view, would make it impossible, impracticable or commercially unreasonable to pursue the development and commercialization of the Product, such as (without limitation) safety issues, efficacy issues, regulatory issues or other justifiable reasons which would have a material adverse effect on the development and commercialization of the Product, Licensee may, in its sole discretion, but in consultation with Licensor, terminate this Agreement by written notice to Licensor, such notice to be effective on its receipt.
Appears in 2 contracts
Sources: License and Supply Agreement (Light Sciences Oncology Inc), License and Supply Agreement (Light Sciences Oncology Inc)